RecruitingPhase 2NCT07235293

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer

Sponsor

Kahr Bio Australia Pty Ltd

Enrollment

90 participants

Start Date

Jan 16, 2026

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer

Summary

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new combination treatment — a drug called DSP107 plus the immunotherapy atezolizumab — compared to a drug called fruquintinib, for people with colorectal cancer that has spread and stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older with a life expectancy of more than 3 months - You have confirmed colorectal cancer (a specific molecular type called MSS/pMMR) that has spread and progressed through previous treatments - You have received no more than 3 prior lines of treatment - You have measurable tumors on imaging **You may NOT be eligible if...** - You have brain metastases that are not stable - You have unresolved significant side effects from prior cancer treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDSP107 + Atezolizumab

DSP107 infusion begins \~30 (±10) minutes after completion of atezolizumab infusion on Day 1.

DRUGFruquintinib

5 mg orally, once daily (with or without food), on Days 1-21 of each 28-day cycle, followed by 7 days off.

Locations(16)

University of Colarodo Cancer Center

Aurora, Colorado, United States

Mayo Clinic

Florida City, Florida, United States

Duke University Medical Center - Duke Cancer Center

Durham, North Carolina, United States

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

The University of Texas MD Anderson Cancer Center

Texas City, Texas, United States

The Queen Elizabeth Hospital

Woodville, Adelaide, Australia

Chris O'brien Lifehouse

Camperdown, New South Wales, Australia

Westmead Hospital

Westmead, New South Wales, Australia

Icon Cancer Centre

South Brisbane, Queensland, Australia

Flinders Medical Centre SA

Bedford Park, South Australia, Australia

Monash Health

Clayton, Victoria, Australia

Footscray Hospital - Western Health

Footscray, Victoria, Australia

Austin Health

Heidelberg, Victoria, Australia

Alfred Hospital

Melbourne, Victoria, Australia

Sunshine Hospital - Western Health

Saint Albans, Victoria, Australia

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07235293

Related Trials

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT052868141 location

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations